{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=13",
    "query": {
      "condition": "Oral Cavity",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 6514,
    "total_pages": 652,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T14:01:56.776Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01682031",
      "title": "Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapeutic Agent Toxicity",
        "Mucositis",
        "Radiation Toxicity",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Xerostomia"
      ],
      "interventions": [
        {
          "name": "selenomethionine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-06",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-22",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682031"
    },
    {
      "nct_id": "NCT03302637",
      "title": "Oral Microbiome and Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "16S rRNA gene sequencing assay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "55 Years to 74 Years"
      },
      "enrollment_count": 732,
      "start_date": "1992-12-01",
      "completion_date": "2010-12-01",
      "has_results": false,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03302637"
    },
    {
      "nct_id": "NCT03421145",
      "title": "A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Plaque"
      ],
      "interventions": [
        {
          "name": "3M™ Oral Rinse",
          "type": "DEVICE"
        },
        {
          "name": "Vehicle Control Oral Rinse",
          "type": "OTHER"
        },
        {
          "name": "PerioShield™ Oral Health Rinse",
          "type": "DEVICE"
        },
        {
          "name": "Water",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Solventum US LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-12-17",
      "completion_date": "2019-01-17",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421145"
    },
    {
      "nct_id": "NCT04901507",
      "title": "Effects of an External Oral Irrigation Device on Patients With Dry Mouth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Xerostomia"
      ],
      "interventions": [
        {
          "name": "The Voutia System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-05-20",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04901507"
    },
    {
      "nct_id": "NCT05934292",
      "title": "Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Enlicitide Decanoate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 33,
      "start_date": "2023-07-20",
      "completion_date": "2024-01-19",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 5,
      "location_summary": "Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05934292"
    },
    {
      "nct_id": "NCT02786537",
      "title": "Study of Oral Treatments for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF/LDV (sofosbuvir/ledipasvir)",
          "type": "DRUG"
        },
        {
          "name": "PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)",
          "type": "DRUG"
        },
        {
          "name": "EBR/GZR (elbasvir/grazoprevir)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1275,
      "start_date": "2016-06",
      "completion_date": "2020-09-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 38,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786537"
    },
    {
      "nct_id": "NCT02066402",
      "title": "Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Tedizolid (BAY119-2631)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tedizolid (BAY119-2631)",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Placebo Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 598,
      "start_date": "2014-03-04",
      "completion_date": "2016-04-18",
      "has_results": true,
      "last_update_posted_date": "2017-06-07",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 5,
      "location_summary": "Chula Vista, California • La Mesa, California • Oceanside, California + 2 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02066402"
    },
    {
      "nct_id": "NCT03167957",
      "title": "Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vulvovaginal Candidiases",
        "Yeast Infection",
        "Vulvovaginitis",
        "Yeast Infection Vaginal",
        "Candidiasis, Vulvovaginal"
      ],
      "interventions": [
        {
          "name": "Oral Encochleated Amphotericin B (CAMB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matinas BioPharma Nanotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2019-12",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03167957"
    },
    {
      "nct_id": "NCT02047981",
      "title": "Mortality Reduction After Oral Azithromycin: Mortality Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Childhood Mortality"
      ],
      "interventions": [
        {
          "name": "Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "1 Month to 60 Months"
      },
      "enrollment_count": 190238,
      "start_date": "2014-12",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02047981"
    },
    {
      "nct_id": "NCT00253019",
      "title": "A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Contraception"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 45 Years · Female only"
      },
      "enrollment_count": 321,
      "start_date": "2004-10",
      "completion_date": "2005-11",
      "has_results": true,
      "last_update_posted_date": "2013-08-21",
      "last_synced_at": "2026-10-22T14:01:56.776Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253019"
    }
  ]
}